What caused BRNS's surprising EPS surge in Q3 2024?

Barinthus Biotherapeutics (BRNS) experienced a negative EPS of $0.21 in Q3 2024, which is a decrease from the previous quarter's EPS of -$0.43. Therefore, it is not accurate to say that there was an "EPS surge" in Q3 2024. However, I can provide insights into the factors contributing to the company's financial performance in Q3 2024.

1. **Revenue from License Sales**: Barinthus Biotherapeutics reported a significant increase in license revenue, attributed to additional commercial sales of Vaxzevria by AstraZeneca. This indicates that the company's revenue was positively impacted by the sales of this drug.
2. **Strategic Cost Management**: The company's loss from operations improved to $67.97 million, down from the previous year, due to decreased operating expenses and increased revenue. This suggests that Barinthus Biotherapeutics implemented cost-saving measures, which contributed to the improvement in financial performance.

In conclusion, the negative EPS in Q3 2024 can be attributed to a combination of increased revenue from license sales and strategic cost management.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|BRNS|BRNS.O|Barinthus|2024 Q1|16.66666666666666|-0.4|185|
|BRNS|BRNS.O|Barinthus|2024 Q2|30.64516129032258|-0.43|185|
|BRNS|BRNS.O|Barinthus|2024 Q3|43.24324324324324|-0.21|185|